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Background. InIdiopathicDilatedCardiomyopathy(IDC)animbalancebetweenmyocardial
oxygen consumptionand supply has been postulated. The ensuing subclinical myocardialischemia
may contribute to progressive deterioration of LV function. b-blocker is the therapy of choice in
these patients. However, not all patients respond to the same extent. The aim of this study was to
elucidate whether differences between responders and non-responders can be identiﬁed with
respect to regional myocardial perfusion reserve (MPR) and contractile performance.
Methods. Patients with newly diagnosed IDC underwent Positron Emission Tomography
(PET)scanningusingboth
13N-ammoniaasaperfusiontracer(baselineanddipyridamolestress),
and
18F-ﬂuoro-deoxyglucoseasametabolismtracer,andadobutaminestressMRI.MRIandPET
were repeated 6 months after maximalb-blocker therapy. MPR (assessed byPET) as well as wall
motion score (WMS, assessed by MRI) were evaluated in a 17 segment-model. Functional
response to b-blocker therapy was assigned as a stable or improved LVEF or diminished LVEF.
Results. Sixteenpatientswereincluded(age47.9 ± 11.5 years;12males,LVEF28.6 ± 8.4%).
Seven patients showed improved LVEF (9.7 ± 3.1%), and nine patients did not show improved
LVEF (23.4 ± 3.9%). MPR improved signiﬁcantly in responders (1.56 ± .23 to 1.93 ± .49,
P 5 .049), and MPR decreased in non-responders; however, not signiﬁcantly (1.98 ± .70 to
1.61 ± .28, P 5 .064), but was signiﬁcantly different between both groups (P 5 .017) after
b-blocker therapy. A signiﬁcant correlation was found between change in perfusion reserve and
changeinLVEF:adecreaseinperfusionreservewasassociatedwithadecreaseinLVEFandvice
versa.Summedrestscoreofwallmotioninrespondersimprovedfrom26to21(P 5 .022)whereas
in non-responders no change was observed from 26 to 25) (P 5 ns). Summed stress score of wall
motion in responders improved from 23 to 21 (P 5 .027) whereas in non-responders no change
was observed from 27 to 26) (P 5 ns).
Conclusion. InIDCpatients,globalaswellasregionalimprovementafterinitiationofb-blocker
treatmentisaccompaniedbyanimprovementinregionalperfusionparameters.Ontheotherhandin
IDCpatientswithfurtherleftventricularfunctiondeteriorationafterinitiationofb-blockertherapy
this is accompanied by a decrease in perfusion reserve. (J Nucl Cardiol 2010;17:479–85.)
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INTRODUCTION
After the description of a beneﬁcial effect of beta-
blocker therapy in a ﬁrst small series of patients
1 many
reports have followed and at present b-blocker therapy is
standard in heart failure patients (ESC guidelines).
However, it is known that patients respond highly vari-
able to beta-blocker therapy.
2-4 Non-response percent-
ages up to 18% have been found.
5 Identiﬁcation of the
cause of this variability may further tailor individ-
ual treatment approaches and perhaps give insights in
pathophysiologic mechanisms. Elucidation of the
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479relation between myocardial perfusion and contractility
in heart failure patients may shed new light on the pro-
gressive deterioration of left ventricular (LV) function.
In a previous study, we have showed that in idiopathic
dilated cardiomyopathy regions with a lower myocardial
perfusion reserve (MPR) are present. Furthermore, we
found that global systolic wall stress correlated nega-
tively with MPR.
6,7 It has therefore been postulated that
progressive deterioration is in part a consequence of
ischemic episodes.
8 One of the possible mechanisms by
which b-blocker therapy that are so successful in heart
failure may be the effects on oxygen demand and supply.
Idiopathic dilated cardiomyopathy (IDC) is a dis-
ease characterized by dilated, poorly contracting ven-
tricles, in the absence of coronary artery disease or
primary valvular disease, or other speciﬁed causes of
myocardial dysfunction.
It has been shown that endothelial function is
impaired in patients with IDC,
9 although the epicardial
coronary arteries do not show signiﬁcant abnormalities.
Also myocardial perfusion abnormalities have been
found.
10 Myocardial ischemia as a cause for the pro-
gression of the disease could be caused by microvascular
abnormalities, endothelial dysfunction, autonomic dis-
regulation of the microvasculature, and high intramural
pressure, due to increased Laplace wall stress.
11 This
may cause myocardial stunning or hibernation, and give
rise to myocardial ﬁbrosis, which promotes further LV
dysfunction and dilatation.
12
We have previously found ischemia-like myocardial
contractile responses during dobutamine stress echo-
cardiography in patients with IDC.
13 Furthermore, we
have observed a relation between ischemia and LV
dysfunction
14 and a decreased MPR in patients with
IDC.
7 In addition, low MPR was paralleled by high LV
systolic wall stress.
7 b-blocker therapy has been recog-
nized as an excellent treatment for heart failure,
including IDC,
15 however, the prognosis of patients in
whom b-blockers are ineffective is poor. b-blocker
therapy may worsen heart failure.
5 Prediction of
b-blocker efﬁcacy could be useful in tailoring the
treatment regimen of heart failure patients.
16 Previously,
Bennett et al, described the effects of metoprolol on rest
regional perfusion in six patients with chronic heart
failure due to IDC. They found a small increase in LVEF
without improved regional perfusion.
17 The question
remains what the effect of early initiation of beta-
blocker therapy is in IDC patients in the early stages of
the disease. In this respect not just rest perfusion but
especially perfusion reserve is of our major interest.
18
The purpose of this study was to substantiate whe-
ther the relation between MPR assessed with positron
emission tomography (PET) and ischemic wall motion
abnormalities during dobutamine stress magnetic
resonance imaging (MRI) is different between respond-
ers and non-responders after b-blocker treatment.
METHODS
Study Group
Patients with newly diagnosed IDC and mild chronic
heart failure (CHF) were eligible for the study. All patients
underwent coronary angiography, which showed normal epi-
cardial coronary arteries. The diagnosis of IDC, was based
on a combination of clinical variables (LV dilation, global
decreased contraction patterns) and the absence of epicardial
coronary artery disease, and the absence of other clear causes
of cardiomyopathy (signiﬁcant valvular disease, alcohol abuse,
use of cardiotoxic agents in the past, like adriamycine, or
active myocarditis). None of the patients were on b-blocker
therapy at the start of this study. PET as well as MRI scanning
was performed before initiation of b-blocker therapy. Other
medication such as angiotensin converting enzyme (ACE)
inhibitors, and diuretics were allowed. After the ﬁrst PET and
MRI scan patients were titrated up to the maximal tolerated
b-blocker dose (up to 200 mg metoprolol per day) and PET
and MRI were repeated after 6 months. Patients with systemic
hypertension (systolic blood pressure [150 mm Hg, diastolic
blood pressure [95 mm Hg), diabetes mellitus, hypercholes-
terolemia ([6 mmol  L
-1) or any other systemic illness were
excluded. All patients gave written, informed consent, and the
protocol was approved by the Institutional Review Board.
Patients were identiﬁed as responders or non-responders.
Functional response to b-blocker therapy was assigned as a
stable or improved LV ejection fraction (LVEF) or diminished
LVEF.
19,20
Protocol for PET Imaging
Patients underwent dynamic rest
13N-ammonia,
13N-ammonia dipyridamole stress and gated
18FDG PET
imaging using a one-day protocol. In brief, PET studies were
performed after patients had discontinued vasoactive medica-
tion for ﬁve plasma half-lives and had refrained from
caffeinated beverages for a minimum of 12 h before the studies.
Imaging was performed in the supine position with a Siemens
Ecat Exact HR ? PET camera (Siemens CTI, Knoxville Ten-
nessee, USA). Measured resolution of the system was 6 mm at
full width half maximum. Data were automatically corrected
for accidental coincidence and dead time. Patients were posi-
tioned with the help of a rectilinear scan. Photon attenuation
was measured using a retractable external ring source ﬁlled
with germanium-68/gallium-68. Dipyridamole perfusion
imaging was performed infusing dipyridamole (.56 mg  kg
-1
in 4 minutes). Imaging was started by injecting 400 MBq of
13N-ammonia 6 minutes after the start of dipyridamole infusion
and continued for 15 minutes.
To stimulate
18FDG uptake, patients were given 75 g of
glucose orally just before scanning or were given 500 mg
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culating free fatty acids 90 minutes before the scanning
procedure. To prevent side-effects of acipimox (e.g., skin
rash), 250 mg of aspirin was administered orally 5 minutes
before acipimox intake. After completion of the
13N-ammonia
data acquisition, 200 MBq of
18FDG was injected intrave-
nously, followed by a PET dynamic acquisition procedure. The
total
18FDG PET acquisition time was 40 minutes, with the last
20 minutes acquired in gated mode with 16 frames per cardiac
cycle. The length of each gate was based on the current
RR-interval. The RR-interval was allowed to vary ±10%. Data
were corrected for attenuation using the transmission scan and
were reconstructed using ﬁltered back-projection (Hann ﬁlter:
.5 pixels/cycle).
Analysis of PET Data
From the PET data, dynamic parametric polar maps were
constructed.
21 Myocardial blood ﬂow data were corrected for
partial volume effect and spill over and quantiﬁed by the
Hutchins model.
22 Brieﬂy, myocardial and blood time-activity
curves manually derived from regions of interest over the heart
and ventricular chamber are ﬁtted using a three compartment
model for
13N-ammonia, yielding rate constants for tracer
uptake and retention. Rest, stress, and perfusion ﬂow reserve
(dipyridamole/rest ratio) was calculated by dividing the dipy-
ridamole
13N-ammonia stress study with the
13N-ammonia rest
study. Rest
13N-ammonia was corrected for heart rate and
blood pressure product.
Regional FDG metabolism in the segment with the
highest myocardial perfusion during dipyridamole stress was
assigned as the optimal FDG metabolic value. The remaining
FDG segments were normalized on this segment. Regional
FDG metabolism was reduced when FDG metabolism was
\50% (abnormal FDG segments) and normal when FDG was
C50% (normal FDG segments). The last frames (20 minutes
acquisition time) of the dynamic gated FDG PET studies were
summed and transformed into static studies and used for fur-
ther data analysis with the help of the quantitative gated
SPECT (QGS) program. Regional MPR as well as FDG
metabolism were evaluated in an automatically derived 17
segment-model. Based on the gated FDG images, left ven-
tricular end systolic (LVESV) and end diastolic volumes
(LVEDV) as well as left ventricular ejection fraction (LVEF)
were computed.
23
PROTOCOL FOR MRI IMAGING
DSMR was performed at a 1.5 Tesla MRI
System (Magnetom Sonata; Siemens Medical Solu-
tions; Erlangen; Germany) according to a standard
dobutamine-atropine stress protocol (5, 10, 20, and
30 lg  kg
-1  min
-1 dobutamine) until 85% of the age-
predicted target heart rate was achieved. Imaging at each
stress level was performed in 1 long-, and 3 short-axis
views and contiguous short-axis views at peak stress
using a segmented steady-state free precession sequence
(TR 3 ms, TE 1.5 ms, FA 60, 15 views per segment).
Myocardial segments (17 segment-model) were evalu-
ated by a panel of three observers (DL, PvdV, RAT).
Wall motion score (WMS) for each individual segment
was given: 1 = normal, 2 = hypokinetic, 3 = akinetic,
4 = dyskinetic. Summed rest score (SRS) = the total
summed wall motion score during rest MRI; summed
stress score (SSS) = the total summed wall motion
score during dobutamine stress. Myocardial ischemia
was deﬁned by new or worsening wall motion abnor-
malities in at least one myocardial segment during dobu-
tamine stress.
STATISTICAL ANALYSIS
Data were expressed as mean ± SD. Categorical
measures are presented as frequencies with percent-
ages. Patients whose LVEF had improved by more than
5% were deﬁned as responders. Differences between
responders and non-responders were compared with
t-test, Wilcoxon rank-sum test, and Chi-square when
appropriate. A P-value\.05 was considered signiﬁcant.
RESULTS
Patients
Between May 2003 and March 2007 a total of 29
eligible patients (age 50 ± 13; 21 male) have been
selected for this study. Eight of them did not give
informed consent or had an indication for ICD implan-
tation, 5 patients had a MRI of low quality, the
remaining 16 patients are subject of this study (age
47.9 ± 11.5 years; 12 male). Left ventricular ejection
fraction before inclusion was 28.6 ± 8.4%. Four patients
were judged to have heart failure NYHA class I, 11 class
II, and 1 class III. The majority of patients were treated
with an ACE-inhibitor, almost half of the patients with
diuretics (Table 1).
Global Analysis Responders
and Non-Responders
Mean LVEF of responders (n = 7) at baseline was
28.4% ± 7.5 and improved to 38.1% ± 6.9 (P\.0001),
whereas mean LVEF of non-responders (n = 9 (56%))
at baseline was 30.3% ± 8.4 and decreased to 27.4% ±
10.2 (P = .029) (Table 2). A lower MPR at baseline
was found in the responders vs. the non-responders,
whereas a signiﬁcant relation between change in MPR
and change in LVEF was found (Figure 1). MPR
improved signiﬁcantly in responders (1.56 ± .23 to
1.93 ± .49, P = .049), whereas a small non-signiﬁcant
decrease was observed in non-responders (1.98 ± .70 to
Journal of Nuclear Cardiology Slart et al 481
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b-blocker therapy was different between the two groups
(P = .017). The number of normal FDG segments
increased in responders while in non-responders a
decrease was observed (16 vs. -14, respectively; P =
.028). The change in the number of abnormal FDG
segments did not show any differences between the two
groups (-2 vs. -5, respectively; P = .17). Summed rest
score of wall motion in responders improved from 26 to
21 (P = .022) whereas in non-responders no change was
observed from 26 to 25) (P = ns). Summed stress score
of wall motion in responders improved from 23 to 21
(P = .027) whereas in non-responders no change was
observed from 27 to 26) (P = ns).
Segmental Analysis
At baseline the mean MPR per segment was
1.79 ± .67 and after b-blocker therapy it was 1.75 ± .56
(P = .32). In non-responders the mean MPR per seg-
ment was 1.98 ± .70 and after b-blocker therapy it was
1.61 ± .28 (P = .05). Whereas in responders the mean
MPR per segment was 1.56 ± .23 and after b-blocker
therapy it was 1.93 ± .70 (P = .049). On FDG PET in
the responders a lower number of non-viable as well as
viable-ischemic segments were found. After b-blocker
therapy the number of normal FDG segments increased
and the number of abnormal FDG segments decreased in
responders. The opposite appeared in non-responders
(Table 2).
A total of 269 segments could be analyzed at
baseline on MRI, after 6 months of maximal b-blocker
treatment 266 segments. Mean WMS per segment at rest
baseline was 1.56 ± .83 and during dobutamine stress
1.49 ± .90 (P = ns) with a mean sum difference score
(SDS) of -17 (36 segments improved, 20 segments
deteriorated). After b-blocker treatment at rest WMS
was 1.39 ± .78, and during dobutamine stress of 1.43 ±
.83 (P = ns) with a SDS of 9 (23 segments improved, 27
segments deteriorated). Segments that improved during
dobutamine stress MRI had an MPR of 2.01 ± .50,
segments that deteriorated had an MPR of 1.74 ± .47
Table 1. Characteristics of responders and non-responders (LVEF)
Responders
(n 5 7)
Non-responders
(n 5 9) P value
Gender F/M 2/5 3/7 .61
Mean age (years ± SD) 56.4 ± 10.9 45.9 ± 9.7 .032
BMI (kg m
-2 ± SD) 25.7 ± 3.9 28.6 ± 4.3 .46
Systolic blood pressure (mm Hg ± SD) 142 ± 22 138 ± 24 .70
Diastolic blood pressure (mm Hg ± SD) 91 ± 19 85 ± 10 .47
Heart rate (beats min
-1 ± SD) 71 ± 10 72 ± 12 .82
Atrial ﬁbrillation (n) 0 1 .55
Hemoglobin (mmol L
-1 ± SD) 9.2 ± .8 8.8 ± .70 .43
Creatinin (lmol L
-1 ± SD) 84 ± 9 83 ± 22 .88
VO2max (mL min
-1 kg
-1 ± SD) 27 ± 15 26 ± 6 .97
Smoking 1 1 1
NYHA class .39
I1 3
II 6 5
III 0 1
IV – –
Aspirin 1 1 1
Coumarin 1 0 .38
ACE-inhibitor 4 5 .94
Angiotensin receptor-I antagonist 2 2 1
Calcium antagonist 0 3 .090
Digoxin 1 2 .68
Cordarone 0 0 1
Statin 0 1 .36
Diuretics 2 3 .69
BMI, Body mass index.
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improvement and WMS worsening before and after
b-blocker treatment was signiﬁcantly different (P = .01,
Figure 2).
DISCUSSION
In the present study we show that patients in whom
b-blocker elicited a beneﬁcial MPR response also had an
improvement in LVEF. The improvement in MPR sig-
niﬁcantly related to improvement in LV function. The
opposite was found in patients with an unfavorable
response to b-blocker therapy. They had a decrease in
MPR which was accompanied by a decrease in LVEF.
Our present ﬁndings corroborate coronary ﬂow reserve
measurements in IDC patients.
24 In that study also a
correlation between regional ﬂow reserve and regional
contractile function was found. In responders non-viable
segments shifted to an increased number of viable seg-
ments, whereas in non-responders the opposite was
noticed. Myocardium subjected to repetitive stunning
based on microvascular pathology may show a pro-
longed yet reversible reduction in systolic function that
can be associated with a signiﬁcant downregulation of
glucose and oxidative metabolism despite relative nor-
mal myocardial blood ﬂow.
25 b-blocker therapy restores
Table 2. PET and MRI ﬁndings of responders and non-responders
MRI and PET data
LVEF (% ± SD) baseline 28.4 ± 7.5 30.3 ± 8.4 P = .32
Difference LVEF (% ± SD) b-blocker 9.7 ± 3.1 -3.4 ± 3.9 P\.0001
Rest myocardial perfusion ± SD baseline
(mL min
-1  100 mg
-1)
55.2 ± 13.3 58.2 ± 18.2 P = .86
Stress myocardial perfusion ± SD baseline
(mL min
-1  100 mg
-1)
85.4 ± 24.8 106.1 ± 28.5 P = .028
Rest myocardial perfusion ± SD b-blocker
(mL min
-1  100 mg
-1)
55 ± 11.9 53.4 ± 19.6 P = .31
Stress myocardial perfusion ± SD b-blocker
(mL min
-1  100 mg
-1)
115.5 ± 70.2 82.7 ± 28.9 P = .128
MPR baseline ± SD 1.56 ± .23 1.98 ± .70 P = .07
Difference MPR b-blocker ± SD .37 ± .49 -.37 ± .66 P = .017
WMS SRS baseline (range) 26 (19–35) 26.1 (16–42) P = .95
WMS SSS baseline (range) 23 (17–35) 27.3 (17–45) P = .31
WMS SDS baseline (range) -3( -12 to 3) .6 (-8 to 13) P = .36
WMS SRS b-blocker (range) 21 (11–32) 25.4 (17–45) P = .67
WMS SSS b-blocker (range) 21 (11–32) 26 (17–46) P = .39
WMS SDS b-blocker (range) -.4 (-3t o2 ) . 6( -10 to 18) P = .98
Mean number of normal FDG segments baseline (range) 2.6 (0–7) 5.3 (1–10) P = .046
Mean number of abnormal FDG segments baseline
(range)
.23 (0–2) 1.4 (0–6) P = .19
Mean number of normal FDG segments b-blocker (range) 4.9 (0–11) 3.8 (1–9) P = .55
Mean number of abnormal FDG segments b-blocker
(range)
0 (0) 2 (0–7) P = .010
LVEF, Left ventricular ejection fraction; MPR, myocardial perfusion reserve; WMS, motion score; SRS, summed rest score; SSS,
summed stress score; SDS, summed differences score.
y = 6.4389x + 2.9228
r = 0.61; p=0.012
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Figure 1. Relation between change in myocardial perfusion
reserve (MPR) and change in left ventricular ejection fraction
(LVEF).
Journal of Nuclear Cardiology Slart et al 483
Volume 17, Number 3;479–85 Myocardial perfusion reserve and contractile patternthe wall motion disorder, and this may lead to normal-
ization of glucose metabolism, mainly in segments with
relative low MPR, as visible in the non-responders.
Hasegawa et al, found that myocardial FDG metabolism
in patients with reduced LVEF in the absence of sig-
niﬁcant coronary artery disease could be used as a
predictor of LVEF improvement after b-blocker ther-
apy.
16 We observed in our study that the number of
normal FDG segments increased in responders while in
non-responders a decrease was observed. Heilbrunn et al
suggested improved contractility to be directly related to
b-receptor upregulation.
26 Bennett et al, found conﬂict-
ing results between patients with ischemic cardiomy-
opathy and dilated, non-ischemic cardiomyopathy.
17
Patients with non-ischemic cardiomyopathy showed no
improvement after b-blocker therapy. Their results are
in agreement with our study, we also did not ﬁnd dif-
ferences in rest myocardial perfusion before and after
b-blocker therapy. However, we evaluated the MPR
after dipyridamole and observed differences between
responders and non-responders. Of note, compared to
our study, LVEF in their study was severely reduced
(mean LVEF 13%; our study 28.4%) and patients were
deﬁned as chronic heart failure whereas we included
newly diagnosed patients. Severe LV dysfunction will
lead to more remodeling and is accompanied by ﬁbrosis
formation.
12
The question about cause or consequence of the
reduction in MPR cannot precisely be answered. How-
ever, it is remarkable that a low perfusion reserve at
baseline was not associated with a further deterioration
and vice versa a high baseline MPR was not associated
with a LV function improvement. This may imply a
reverse relationship; however, complicated mechanisms
may be involved dealing with redistributing perfusion
between epi- and endocardial layers. There may be a
signiﬁcant transmural gradient in the density of
b-receptors in ischemic and non-ischemic cardiomyop-
athy. Measurement of receptor density using PET
11C-CGP as radioligand could also be an important tool
for estimation of b-receptor status during treatment,
since it directly reﬂects changes in myocardial contrac-
tility.
27 A limitation of this study is the relative small
number of included patients; however, the segmental
analysis justiﬁes our conclusion.
In conclusion IDC patients responding to b-blocker
therapy show an improvement in MPR in concert with
improved wall motion parameters. These data under-
score the importance of subclinical ischemia in patients
with IDC and may direct further research in the eluci-
dation of the difference between responders and non-
responders.
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